Logo

American Heart Association

  2
  0


Final ID: MDP582

Reverse J-shaped Associations of Serum Hypoxia-inducible Factor 1α Levels With All-cause Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study

Abstract Body (Do not enter title and authors here): Background: Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric transcription factor composed of a constitutively expressed β subunit (HIF-1β) and an oxygen-dependent α subunit (HIF-1α). HIF-1α has an important protective effect on the pathophysiology underlying coronary artery disease (CAD). However, the association between serum HIF-1α levels and mortality in patients with suspected or known CAD is unknown.
Methods and Results: Serum levels of HIF-1α were measured in 2,418 patients with suspected or known CAD using a commercially available enzyme-linked immunosorbent assay kit (sensitivity, 30 pg/mL). The outcomes were all-cause death, cardiovascular (CV) death, and non-CV death. Patients were divided into 5 groups according to HIF-1α levels; below the sensitivity (Q0, <30 pg/mL) and quartiles of measurable HIF-1α levels (Q1, 31-127; Q2, 128-303; Q3, 307-765; Q4, 774-4131 pg/mL). Patients were followed up over a 6-year period. During the follow-up, 536 (22.2%) deaths occurred, including 166 (6.9%) CV deaths, 326 (13.5%) non-CV deaths, and 44 (1.8%) undetermined deaths. At baseline, HIF-1α levels were significantly and inversely associated with the rate of current smoker (P<0.001), and showed significant U-shaped associations with age (P=0.016) and high-sensitivity C-reactive protein levels (P<0.001). Interestingly, HIF-1α levels exhibited U-shaped associations with incidence of all-cause, CV death, and non-CV death (Figure 1). Since the rates of incident outcomes were similar among Q1-Q3, we combined these 3 groups into the reference group for Cox proportional hazard analyses thereafter. After adjustment for potential clinical confounders and established CV biomarkers, the low HIF-1α level (Q0) was significantly associated with all-cause death (adjusted hazard ratio [aHR], 1.38; 95% confidence interval [CI], 1.02–1.91), but not with CV death (aHR, 1.12; 95% CI, 0.68–1.97) or non-CV death (aHR, 1.45; 95% CI, 0.98–2.23), while the high HIF-1α level (Q4) was not significantly associated with all-cause death (aHR, 1.12; 95% CI, 0.66–1.86), CV death (aHR, 0.76; 95% CI, 0.28–1.86), or non-CV death (aHR, 1.17; 95% CI, 0.58–2.25).
Conclusions: We first demonstrated that serum HIF-1α levels exhibited a reverse J-shaped association with the risk of all-cause mortality in patients with suspected or known CAD.
  • Iguchi, Moritake  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Takenaka, Takashi  ( NHO Hokkaido Medical Center , Sapporo , Japan )
  • Morita, Yukiko  ( NHO Sagamihara National Hospital , Sagamihara , Japan )
  • Nakamura, Toshihiro  ( NHO Kyushu Medical Center , Fukuoka , Japan )
  • Fujimoto, Kazuteru  ( NHO Kumamoto Medical Center , Kumamoto , Japan )
  • Matsubara, Hiromi  ( NHO Okayama Medical Center , Okayama , Japan )
  • Kato, Toru  ( NHO Tochigi Medical Center , Utsunomiya , Japan )
  • Unoki, Takashi  ( Saiseikai Kumamoto Hospital , Kumamoto , Japan )
  • Takagi, Daisuke  ( Hirakata Kohsai Hospital , Hirakata , Japan )
  • Wada, Kyohma  ( Japanese Red Cross Kyoto Daini Hospital , Kyoto , Japan )
  • Wada, Miyaka  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Suzuki, Masahiro  ( NHO Saitama Hospital , Wako , Japan )
  • Nakayama, Takumi  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Maeda, Yuka  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Masunaga, Nobutoyo  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Ishii, Mitsuru  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Kotani, Kazuhiko  ( Jichi Medical University , Shimotsuke , Japan )
  • Abe, Mitsuru  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Akao, Masaharu  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Hasegawa, Koji  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Wada, Hiromichi  ( NHO Kyoto Medical Center , Kyoto , Japan )
  • Matsuda, Morihiro  ( NHO Kure Medical Center and Chugoku Cancer Center , Kure , Japan )
  • Ajiro, Yoichi  ( NHO Yokohama Medical Center , Yokohama , Japan )
  • Shinozaki, Tsuyoshi  ( NHO Sendai Medical Center , Sendai , Japan )
  • Sakagami, Satoru  ( NHO Kanazawa Medical Center , Kanazawa , Japan )
  • Yonezawa, Kazuya  ( NHO Hakodate National Hospital , Hakodate , Japan )
  • Shimizu, Masatoshi  ( NHO Kobe Medical Center , Kobe , Japan )
  • Funada, Junichi  ( NHO Ehime Medical Center , Toon , Japan )
  • Author Disclosures:
    Moritake Iguchi: DO NOT have relevant financial relationships | Takashi Takenaka: DO NOT have relevant financial relationships | Yukiko Morita: DO NOT have relevant financial relationships | Toshihiro Nakamura: DO NOT have relevant financial relationships | Kazuteru Fujimoto: No Answer | Hiromi Matsubara: DO have relevant financial relationships ; Advisor:MSD:Active (exists now) ; Speaker:AOP Health:Past (completed) ; Speaker:Nipro:Past (completed) ; Speaker:Bayer:Past (completed) ; Speaker:Nippon Shinyaku:Active (exists now) ; Speaker:Kaneka Medix:Active (exists now) ; Speaker:Mochida Pharmaceutical Co:Active (exists now) ; Speaker:Janssen:Active (exists now) ; Speaker:MSD:Active (exists now) ; Advisor:Bayer:Past (completed) ; Advisor:Janssen:Active (exists now) | Toru Kato: No Answer | Takashi Unoki: DO NOT have relevant financial relationships | Daisuke Takagi: DO NOT have relevant financial relationships | Kyohma Wada: DO NOT have relevant financial relationships | Miyaka Wada: DO NOT have relevant financial relationships | Masahiro Suzuki: DO NOT have relevant financial relationships | Takumi Nakayama: DO NOT have relevant financial relationships | Yuka Maeda: DO NOT have relevant financial relationships | Nobutoyo Masunaga: DO NOT have relevant financial relationships | Mitsuru Ishii: DO NOT have relevant financial relationships | Kazuhiko Kotani: DO NOT have relevant financial relationships | Mitsuru Abe: DO NOT have relevant financial relationships | Masaharu Akao: DO have relevant financial relationships ; Speaker:Pfizer:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Speaker:Bayer Yakuhin:Active (exists now) ; Speaker:Bristol-Myers Squibb:Active (exists now) | Koji Hasegawa: DO NOT have relevant financial relationships | Hiromichi Wada: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott Japan LLC:Past (completed) ; Research Funding (PI or named investigator):Otsuka Pharmaceutical Co.,Ltd.:Past (completed) ; Research Funding (PI or named investigator):Teijin Pharma, Ltd:Past (completed) ; Research Funding (PI or named investigator):Kyowa Kirin Co., Ltd.:Past (completed) ; Research Funding (PI or named investigator):Daiichi Sankyo Co., Ltd.:Past (completed) ; Research Funding (PI or named investigator):Roche Diagnostics K.K.:Past (completed) | Morihiro Matsuda: DO NOT have relevant financial relationships | Yoichi Ajiro: DO NOT have relevant financial relationships | Tsuyoshi Shinozaki: DO NOT have relevant financial relationships | Satoru Sakagami: DO NOT have relevant financial relationships | Kazuya Yonezawa: No Answer | masatoshi shimizu: DO NOT have relevant financial relationships | Junichi Funada: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Biomarkers in ACS

Saturday, 11/16/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
Alpha-1-acid glycoprotein is a potential serum Biomarker for Cerebral Amyloid Angiopathy

Nishigaki Akisato, Matsuura Keita, Ii Yuichiro, Oikawa Shinji, Tomimoto Hidekazu, Shindo Akihiro, Ishikawa Hidehiro, Nishiguchi Yamato, Tachibana Kei, Kato Natsuko, Matsuda Kana, Mori Yurie, Utsunomiya Takaya, Matsuyama Hirofumi

Physician follow up and cardiac testing after a first diagnosis with secondary vs. primary atrial fibrillation in-hospital

Mohammed Basma, Abdel-qadir Husam, Fang Jiming, Dorian Paul, Lee Douglas, Ha Andrew, Jackevicius Cynthia, Ko Dennis, Austin Peter, Singh Sheldon

More abstracts from these authors:
The Cardiomyocyte Hypertrophy Inhibitor RFN-409, Identified by High Throughput Screening Assay, Suppresses Pressure Overload-induced Systolic Dysfunction in Mice by Suppressing p38 Activity

Irokawa Yudai, Katanasaka Yasufumi, Hasegawa Koji, Morimoto Tatsuya, Katagiri Takahiro, Maeda Risa, Shimizu Satoshi, Funamoto Masafumi, Hamabe Toshihide, Sunagawa Yoichi, Kawase Yuto, Naruta Ryuya

Impact of Anemia on the Prediction of Galectin-3 for Cause-specific Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study

Wada Hiromichi, Takenaka Takashi, Morita Yukiko, Nakamura Toshihiro, Fujimoto Kazuteru, Matsubara Hiromi, Kato Toru, Unoki Takashi, Takagi Daisuke, Wada Kyohma, Wada Miyaka, Suzuki Masahiro, Nakayama Takumi, Maeda Yuka, Masunaga Nobutoyo, Ishii Mitsuru, Kotani Kazuhiko, Abe Mitsuru, Akao Masaharu, Hasegawa Koji, Matsuda Morihiro, Ajiro Yoichi, Shinozaki Tsuyoshi, Sakagami Satoru, Yonezawa Kazuya, Shimizu Masatoshi, Funada Junichi

You have to be authorized to contact abstract author. Please, Login
Not Available